治疗|诺华达拉非尼联合曲美替尼双靶组合疗法新适应症获批，肺癌患者迎来新选择( 二 ) 中国|组合|研究|适应症|患者

诺华全球药品开发（中国）负责人王兴利医学博士表示：“‘以患者为中心’贯穿于诺华整个研发环节。针对此次达拉非尼联合曲美替尼的新适应症，从研究设计开始，我们就在努力寻找合理且高效的路径，力求尽快把新药带给患者。未来，我们还将继续加速更多中国高发肿瘤新药的全球同步研发及上市。 ”
作为全球领先的跨国药企，诺华目前已经有多款肺癌治疗药物获批，在肿瘤领域更拥有覆盖乳腺癌、肺癌、黑色素瘤、肾癌以及血液疾病等广泛的产品组合和丰富的产品线。诺华致力于提升创新药品的可及性，让更多中国患者尽快获益于创新成果，为他们带来健康和希望。
【1】LEONETTI A, FACCHINETTI F, ROSSI G, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall［J］. Cancer Treat Rev, 2018, 66: 82-94.
【2】HORN L, BAUML J, FORDE P M, et al. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer［J］. Lung Cancer, 2019, 128: 74-90.
【3】O'LEARY C G, ANDELKOVIC V, LADWA R, et al. Targeting BRAF mutations in non-small cell lung cancer［J］. Transl Lung Cancer Res, 2019, 8(6): 1119-1124.
【4】Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4.
【5】Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2.
【6】Odogwu L, Mathieu L, Blumenthal G,et al. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642.
【7】赵媛媛，周建英，范云，等. BRAF V600突变型非小细胞肺癌的治疗进展［J］. 中国癌症杂志, 2021, 31 (12): 1145-1152.
【8】AULIAC J B, BAYLE S, DO P, et al. Efficacy of dabrafenib plus trametinib combination in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019［J］. Cancers (Basel), 2020, 12(12): E3608.
【9】AULIAC J B, BAYLE S, DO P, et al. Efficacy of dabrafenib plus trametinib combination in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019［J］. Cancers (Basel), 2020, 12(12): E3608.
【10】中国临床肿瘤学会. 非小细胞肺癌诊疗指南 (2021)［M］. 北京: 人民卫生出版社, 2021.
Chinese Society of Clinical Oncology. Guidelines for diagnosis and treatment of non-small cell lung cancer (version 2021) ［M］. Beijing: People’s Medical Publishing House, 2021.